Cretostimogene grenadenorepvec is an oncolytic virus commercialized by CG Oncology, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to Globaldata, it is involved in 12 clinical trials, of which 3 were completed, 6 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Cretostimogene grenadenorepvec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Cretostimogene grenadenorepvec is expected to reach an annual total of $351 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Cretostimogene grenadenorepvec Overview
CG-0070 is under development for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer, metastatic bladder cancer and metastatic urothelial cancer. The drug candidate is administered intravesically and intratumoral routes. CG-0070 is the first armed oncolytic virus therapy. It is engineered to secrete GM-CSF, an immune-stimulating hormone, which also serves as the adjuvant in GVAX cancer immunotherapy platform. It was under development for ovarian cancer, glioblastoma multiforme, lung cancer and head and neck cancer and other solid tumors.
CG Oncology Overview
CG Oncology is a late-stage clinical biopharmaceutical company. It develops and commercializes a potential backbone bladder-sparing therapeutic for bladder cancer. The company’s lead candidate cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesical delivered immunotherapy agent that treats non-muscle invasive bladder cancer (NMIBC); and CG0161 preclinical oncological product. The company operates offices in Irvine and Emeryville, the US. CG Oncology is headquartered in Irvine, California, the US.
The company reported revenues of (US Dollars) US$0.2 million for the fiscal year ended December 2023 (FY2023), an increase of 6.8% over FY2022. The operating loss of the company was US$55.5 million in FY2023, compared to an operating loss of US$35.3 million in FY2022. The net loss of the company was US$48.6 million in FY2023, compared to a net loss of US$35.4 million in FY2022.
The company reported revenues of US$0.1 million for the second quarter ended June 2024, a decrease of 79% over the previous quarter.
For a complete picture of Cretostimogene grenadenorepvec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.